Short-course antibiotic therapy in abdominal sepsis with source control: an integrative review
DOI:
https://doi.org/10.5281/zenodo.21798798Keywords:
abdominal sepsis, complicated intra-abdominal infection, short-course antibiotic therapy, source control, antibiotic treatment duration, mortality, antimicrobial resistanceAbstract
Background: Complicated intra-abdominal infection (cIAI) is a leading cause of sepsis in critical care, with variable mortality. Treatment relies on source control and systemic antibiotic therapy. Controversy over optimal duration has challenged prolonged courses (7–14 days) because of increased risk of adverse events, Clostridioides difficile infection and selection of microbial resistance. The STOP-IT trial was a milestone in demonstrating non-inferiority of a fixed four-day antibiotic course in cIAI with adequate source control. Objective: To synthesize evidence on short-course antibiotic therapy in abdominal sepsis with source control. Methods: Integrative review of clinical evidence on antibiotic duration in complicated intra-abdominal infection. Results: Short fixed courses after adequate source control are non-inferior to longer strategies for clinical outcomes in selected patients, with potential benefits regarding adverse events and antimicrobial resistance. Conclusions: After adequate source control, short antibiotic courses are a reasonable strategy in eligible patients; duration should be individualized according to clinical response and local ecology.
References
Napolitano LM. Intra-abdominal infections. Semin Respir Crit Care Med. 2022;43(1):10-27. doi:10.1055/s-0041-1741053
Ahmed S, Wilcox MH, Kirby A. Measuring outcomes in complicated intra-abdominal infections. Curr Opin Gastroenterol. 2020;36(1):1-4. doi:10.1097/mog.0000000000000591
Obst W, Esser T, Kaasch AJ, Geginat G, Meyer F, Croner RS, et al. The need of antimicrobial stewardship in post-operative infectious complications of abdominal surgery. Visc Med. 2022;38(5):345-53. doi:10.1159/000526785
Hellyer TP, Mantle T, McMullan R, Dark P. How to optimise duration of antibiotic treatment in patients with sepsis? BMJ. 2020;371:m4357. doi:10.1136/bmj.m4357
Sheppard D. Short-course antibiotic therapy: the next frontier in antimicrobial stewardship. Can Commun Dis Rep. 2022;48(11-12):496-501. doi:10.14745/ccdr.v48i1112a01
Ng-Kamstra JS, Soo A, McBeth P, Rotstein O, Zuege DJ, Gregson D, et al. STOP signs: a population-based interrupted time series analysis of antibiotic duration for complicated intra-abdominal infection before and after the publication of a landmark RCT. Ann Surg. 2023;277(5):e984-91. doi:10.1097/sla.0000000000005231
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi:10.1136/bmj.n71
Whittemore R, Knafl K. The integrative review: updated methodology. J Adv Nurs. 2005;52(5):546-53. doi:10.1111/j.1365-2648.2005.03621.x
Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919. doi:10.1136/bmj.i4919
Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. doi:10.1136/bmj.l4898
Surat G, Meyer-Sautter P, Rüsch J, Braun-Feldweg J, Germer CT, Lock JF. Retrospective cohort analysis of the effect of antimicrobial stewardship on postoperative antibiotic therapy in complicated intra-abdominal infections: short-course therapy does not compromise patients' safety. Antibiotics (Basel). 2022;11(1):120. doi:10.3390/antibiotics11010120
Vinodhini P, Sureshkumar S, Gurushankari B, Mahalakshmy T, Kate V. Comparison of short-course and conventional antimicrobial duration in mild and moderate complicated intra-abdominal infections: a randomised controlled trial. Sultan Qaboos Univ Med J. 2023;23(2):212-9. doi:10.18295/squmj.1.2023.006
Ahmed S, Brown R, Pettinger R, Vargas-Palacios A, Burke D, Kirby A. The CABI trial: an unblinded parallel group randomised controlled feasibility trial of long-course antibiotic therapy (28 days) compared with short course (≤ 10 days) in the prevention of relapse in adults treated for complicated intra-abdominal infection. J Gastrointest Surg. 2021;25(4):1045-52. doi:10.1007/s11605-020-04545-2
Muñeton-López GA, Rodríguez LFC, Fandiño LCS, Lasso AD, Granados JPA, Salazar YID, et al. Effectiveness of five antibiotic regimens for the treatment of intra-abdominal infection in Bogotá. Surg Infect (Larchmt). 2022;23(10):933-9. doi:10.1089/sur.2022.296
Dulek A, O'Dell JC, Guidry CA. Prolonged therapy is not associated with delayed identification of recurrent intra-abdominal infection. Surg Infect (Larchmt). 2022;23(9):796-800. doi:10.1089/sur.2022.238
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Christirobert Goncalves Neres, Dillion Arpis Braz Ferreira, Eduardo Silva de Araújo, Lucília Maria de Oliveira Cardoso, Tainara Huane da Silva Terra, Maria Eduarda Mihok, Paola Britos (Autor/a)

This work is licensed under a Creative Commons Attribution 4.0 International License.
Articles are distributed under the Creative Commons Attribution 4.0 International — CC BY 4.0 licence. Authors retain copyright and grant the journal the right of first publication. Any reuse must acknowledge authorship, cite the original source and indicate whether changes were made.











